Dômes Pharma continues its international expansion with the opening of Dômes Pharma Limited (Ltd.) in Montreal, effective January 1, 2026. This new subsidiary marks an important step in the Group’s growth strategy in North America.

Canada represents a strategic market for animal health, comparable in size to some major European markets. Initially, the subsidiary will focus on strengthening the Group’s commercial presence among Canadian veterinarians.

Dômes Pharma already has several products registered and marketed in Canada, particularly in ophthalmology. In 2026, the Group also plans to launch a drug range dedicated to poisoning management, with the ambition to gradually expand its portfolio in the coming years.

The Canadian subsidiary will be led by Isabelle Renaud, based in Montreal. With more than 20 years of experience in the animal health industry in North America, she will be responsible for structuring and developing the Group’s activities in the Canadian market.

The opening of the subsidiary will also be accompanied by progressive job creation, with three positions planned in 2026.